Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19

Study Overview
=================
Brief Summary
-----------------
COVID-19, caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is a multisystem disease which primarily involves the respiratory tract. The first case of COVID-19 was identified in late 2019 in the province of Wuhan, China which was followed by the rapid spread of the disease globally, becoming a present-day pandemic. Objectives: The aim of this study was to describe the clinical characteristics, comorbidities and outcome of the critically sick patients with COVID-19 pneumonia admitted in ICU of a tertiary care hospital in Lahore.

Detailed Description
-----------------
Objectives: The aim of this study was to describe the clinical characteristics, comorbidities and outcome of the critically sick patients with COVID-19 pneumonia admitted in ICU of a tertiary care hospital in Lahore. Material & Methods: Study design: Retrospective study. Study Settings: Study was conducted in Fatima Memorial Hospital, Lahore. Study Duration: Study was conducted on Covid-19 patients who were admitted from March 2021 to August 2021.

Official Title
-----------------
Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19 Pneumonia Admitted in Intensive Care Unit of a Tertiary Care Hospital in Lahore, Pakistan: A Retrospective Cohort Study

Conditions
-----------------
COVID-19 Pneumonia

Intervention / Treatment
-----------------
* Combination Product: Patients with COVID-19 Pneumonia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critically sick patients with COVID-19 Pneumonia All admitted ICU patients with a diagnosis of COVID-19 pneumonia Patients having positive reverse transcriptase PCR for COVID-19 Patients with High-resolution computed tomography (HRCT) chest findings suggestive of COVID-related lung injury All patients above 16 years of age with both genders( males and females) Exclusion Criteria: All patients with PCR negative with mild symptoms Patients with No signs of COVID-19 pneumonia on HRCT chest

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with COVID-19 pneumonia<br>These patients were admitted in ICU for management of Covid-19 pneumonia usual care was offered to all patients | Combination Product: Patients with COVID-19 Pneumonia<br>* Patients were offered with usual care of COVID-19 in ICU and we did retrospective study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | The primary endpoint of the study will be to assess the ICU mortality (in percentages% and Numbers) of critically sick patients with COVID-19 pneumonia admitted to the intensive care unit | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comorbidities | we will assess various comorbidities in critically sick patients with COVID-19 pneumonia admitted to the intensive care unit | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Comorbidities, Outcomes, Covid-19